“An Oral, Selective Tyrosine Kinase 2 Inhibitor, BMS-986165, Reduced Absolute Psoriasis Area and Severity Index in a Phase 2 Trial in Psoriasis”. SKIN The Journal of Cutaneous Medicine, vol. 4, no. 5, Sept. 2020, p. s27, https://doi.org/10.25251/skin.4.supp.27.